New drug development: science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
GAO
[2006]
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | II, 47 S. Ill. |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV035220939 | ||
| 003 | DE-604 | ||
| 005 | 20091230 | ||
| 007 | t | ||
| 008 | 081218s2006 xxua||| t|||z00||| eng d | ||
| 010 | |a 2007361062 | ||
| 035 | |a (DE-599)BVBBV035220939 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-M382 | ||
| 050 | 0 | |a RM301.25 | |
| 082 | 0 | |a 615/.19 | |
| 088 | |a GAO-07-49 | ||
| 110 | 2 | |a USA |b Government Accountability Office |e Verfasser |0 (DE-588)10108629-5 |4 aut | |
| 245 | 1 | 0 | |a New drug development |b science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters |c United States Government Accountability Office |
| 246 | 1 | 3 | |a Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts |
| 264 | 1 | |a Washington, D.C. |b GAO |c [2006] | |
| 300 | |a II, 47 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 610 | 2 | 4 | |a United States |b Food and Drug Administration |
| 650 | 4 | |a Drug development |z United States | |
| 650 | 4 | |a Pharmaceutical industry |z United States | |
| 650 | 4 | |a Intellectual property |z United States | |
| 651 | 4 | |a USA | |
| 856 | 4 | 1 | |u http://purl.access.gpo.gov/GPO/LPS77471 |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-017027024 | ||
Datensatz im Suchindex
| _version_ | 1804138484009533440 |
|---|---|
| any_adam_object | |
| author_corporate | USA Government Accountability Office |
| author_corporate_role | aut |
| author_facet | USA Government Accountability Office |
| author_sort | USA Government Accountability Office |
| building | Verbundindex |
| bvnumber | BV035220939 |
| callnumber-first | R - Medicine |
| callnumber-label | RM301 |
| callnumber-raw | RM301.25 |
| callnumber-search | RM301.25 |
| callnumber-sort | RM 3301.25 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ebook |
| ctrlnum | (DE-599)BVBBV035220939 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01411nam a2200385zc 4500</leader><controlfield tag="001">BV035220939</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20091230 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">081218s2006 xxua||| t|||z00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2007361062</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035220939</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM301.25</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield></datafield><datafield tag="088" ind1=" " ind2=" "><subfield code="a">GAO-07-49</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">USA</subfield><subfield code="b">Government Accountability Office</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)10108629-5</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New drug development</subfield><subfield code="b">science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters</subfield><subfield code="c">United States Government Accountability Office</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">GAO</subfield><subfield code="c">[2006]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">II, 47 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States</subfield><subfield code="b">Food and Drug Administration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intellectual property</subfield><subfield code="z">United States</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://purl.access.gpo.gov/GPO/LPS77471</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017027024</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV035220939 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T21:28:55Z |
| institution | BVB |
| institution_GND | (DE-588)10108629-5 |
| language | English |
| lccn | 2007361062 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-017027024 |
| open_access_boolean | 1 |
| owner | DE-M382 |
| owner_facet | DE-M382 |
| physical | II, 47 S. Ill. |
| psigel | ebook |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | GAO |
| record_format | marc |
| spelling | USA Government Accountability Office Verfasser (DE-588)10108629-5 aut New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters United States Government Accountability Office Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts Washington, D.C. GAO [2006] II, 47 S. Ill. txt rdacontent n rdamedia nc rdacarrier United States Food and Drug Administration Drug development United States Pharmaceutical industry United States Intellectual property United States USA http://purl.access.gpo.gov/GPO/LPS77471 kostenfrei Volltext |
| spellingShingle | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters United States Food and Drug Administration Drug development United States Pharmaceutical industry United States Intellectual property United States |
| title | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters |
| title_alt | Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts |
| title_auth | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters |
| title_exact_search | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters |
| title_full | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters United States Government Accountability Office |
| title_fullStr | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters United States Government Accountability Office |
| title_full_unstemmed | New drug development science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters United States Government Accountability Office |
| title_short | New drug development |
| title_sort | new drug development science business regulatory and intellectual property issues cited as hampering drug development efforts report to congressional requesters |
| title_sub | science, business, regulatory, and intellectual property issues cited as hampering drug development efforts ; report to congressional requesters |
| topic | United States Food and Drug Administration Drug development United States Pharmaceutical industry United States Intellectual property United States |
| topic_facet | United States Food and Drug Administration Drug development United States Pharmaceutical industry United States Intellectual property United States USA |
| url | http://purl.access.gpo.gov/GPO/LPS77471 |
| work_keys_str_mv | AT usagovernmentaccountabilityoffice newdrugdevelopmentsciencebusinessregulatoryandintellectualpropertyissuescitedashamperingdrugdevelopmenteffortsreporttocongressionalrequesters AT usagovernmentaccountabilityoffice sciencebusinessregulatoryandintellectualpropertyissuescitedashamperingdrugdevelopmentefforts |